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Abstract Objective Alveolar macrophages play a key role in the development and resolution of
acute respiratory distress syndrome (ARDS), modulating the inﬂammatory response
and the coagulation cascade in lungs. Anti-coagulants may be helpful in the treatment
of ARDS. This study investigated the effects of nebulized heparin on the role of alveolar
macrophages in limiting lung coagulation and inﬂammatory response in an animal
model of acute lung injury (ALI).
Methods Rats were randomized to four experimental groups. In three groups, ALI was
induced by intratracheal instillation of lipopolysaccharide (LPS) and heparin was nebulized
at constant oxygen ﬂow: the LPS/Hep group received nebulized heparin 4 and 8 hours after
injury; the Hep/LPS/Hep group received nebulized heparin 30 minutes before and 4 and
8 hours after LPS-induced injury; the LPS/Sal group received nebulized saline 4 and 8 hours
after injury. The control group received only saline. Animals were exsanguinated 24 hours
after LPS instillation. Lung tissue, bronchoalveolar lavage ﬂuid (BALF) and alveolar macro-
phages isolated from BALF were analysed.
Results LPS increased protein concentration, oedema and neutrophils in BALF as well as
procoagulant and proinﬂammatory mediators in lung tissue and alveolar macrophages. In
lung tissue, nebulized heparin attenuated ALI through decreasing procoagulant (tissue
factor, thrombin–anti-thrombin complexes, ﬁbrin degradation products) and proinﬂam-
matory (interleukin 6, tumour necrosis factor alpha) pathways. In alveolar macrophages,
nebulized heparin reduced expression of procoagulant genes and the effectors of
transforming growth factor beta (Smad 2, Smad 3) and nuclear factor kappa B (p-selectin,
CCL-2). Pre-treatment resulted in more pronounced attenuation.
Conclusion Nebulized heparin reduced pulmonary coagulopathy and inﬂammation
without producing systemic bleeding, partly by modulating alveolar macrophages.
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Introduction
Acute respiratory distress syndrome (ARDS) is amajor cause of
morbidity and mortality (30–40%) in critically ill patients.1,2
Deﬁned by non–heart-failure-related acute respiratory failure
and inﬂammation, ARDS can arise from various local and
systemic insults.3 It is characterized by bilateral pulmonary
inﬁltrates, increased endothelial permeability and oedema.4
Although lung protective ventilation strategy and prone posi-
tionhaveproducedamajorbreakthrough in supportive care of
ARDS patients, an effective pharmacological therapy for ARDS
is not available yet.
Even though neutrophil inﬂux and activation within the
lungs contribute to the induction of ARDS, increasing evidence
suggests that alveolar macrophages are critical to the initiation
and maintenance of the inﬂammatory response and to the
resolutionphase.5,6Morespeciﬁcally, lung inﬂammationduring
ARDS is deeply correlated to the alveolar macrophages pheno-
type, function and cell–cell interactions.6,7 Due to their plasti-
city, macrophages can be proinﬂammatory (M1) or anti-
inﬂammatory activated (M2) depending on environmental
signals. At the initial acute phase of ARDS, classically activated
macrophages (M1) release early response cytokines such as
tumour necrosis factor alpha (TNF-α) or inducible nitric oxide
synthase (iNOS), stimulating the cells of the alveoli and recruit-
ing neutrophils to the alveolar space, amplifying the inﬂamma-
tory response and promoting the elimination of pathogens. At
the resolution phase, alternative macrophages (M2) are acti-
vated releasinganti-inﬂammatorycytokines suchas interleukin
10 (IL-10) or arginase 1 and promoting tissue remodeling.5,7
ARDS is also associated with pulmonary activation of coa-
gulation mediated by the tissue factor (TF) pathway. Exposure
to proinﬂammatory cytokines causes alveolar macrophages
and alveolar epithelial cells to produce TF, the key mediator of
coagulation in severe infections.8 Pulmonary coagulation is
evident in increased markers of thrombin generation, soluble
TFand factorVIIa activity found inbronchoalveolar lavageﬂuid
(BALF) from ARDS patients, together with increased release of
plasminogen activator inhibitor-1 (PAI-1) resulting in de-
creased ﬁbrinolytic activity.9–11
Previous ﬁndings indicate that anti-coagulants may help
restore the coagulation cascade and treat ARDS; however, in
experimental models of acute lung injury (ALI) and in ARDS
patients, the beneﬁcial effects of systemic anti-coagulants
were outweighed by systemic bleeding.12–18 Local adminis-
tration of nebulized anti-coagulants to the lungsmight reduce
the risk of systemic bleeding andmight bemore effective than
intravenous administration.19 Preclinical studies with animal
models of direct and indirect ALI have found that local admin-
istration of nebulized heparin improved pulmonary coagulo-
pathy.20 Intravenous anti-thrombin combinedwith nebulized
heparin and tissue plasminogen activator restored gas ex-
change but not inﬂammation in a model of burn and smoke
inhalation injured sheep.21 In a phase I trial of nebulized
heparin to ARDS patients, the activation of pulmonary coagu-
lationwas reducedwithout producing systemic bleeding.22,23
In addition, nebulized heparin decreased the duration of
mechanical ventilation in burn inhalation injured patients.24
Besides its anti-coagulant effects, intravenously adminis-
tered heparin showed anti-inﬂammatory effects, ameliorat-
ing lipopolysaccharide (LPS)-induced lung injury in rats via
the inhibition of the nitric oxide synthase expression and
transforming growth factor beta (TGF-β)/Smad pathway.25
Heparin was also found to inhibit the nuclear factor kappa B
(NF-κB) pathway in monocytes treated with LPS.26,27
Furthermore, data recently obtained by our group showed
that after LPS injury in human alveolar macrophages heparin
limited the expression of TNF-α and IL-6, while in human
alveolar type II cells heparin inhibited the NF-κB pathway
and their effectors IL-6, MCP-1 and IL-8.28
Since alveolar macrophages play an important role in the
development and resolution of ARDS, modulating the inﬂam-
matory response and the coagulation cascade in lungs, and
heparin exhibits both anti-inﬂammatory and anti-coagulant
properties, the hypothesis of this work was that nebulized
heparin could attenuate ARDS through the involvement of
alveolarmacrophages. Accordingly, the current studyaimed to
assess the effects of nebulized heparin in a rat model of ALI
induced by intratracheal instillation of LPSwith special regard
to the role that alveolar macrophages might have in limiting
the coagulation and the inﬂammatory response. More in de-
tails, we postulated that: (1) in lungs, nebulized heparin
decreases procoagulant markers and inﬂammation in terms
of lungneutrophil inﬂux, oedema, proinﬂammatorycytokines
and histopathology; (2) in alveolar macrophages, nebulized
heparin reduces the effectors of TGF-β and NF-κB pathways
and the expression of procoagulant genes.
Materials and Methods
Animals
We studied 64 pathogen-free male Sprague-Dawley rats
(8 weeks old; 250–300 g; Charles River, Chatillon-sur-Chalar-
onne, France) housed in 12-hour light–dark-cycle, air-condi-
tioned (23°C and 60% relative humidity) quarters with free
access to standard food pellets (A04; Panlab, Barcelona, Spain)
and tap water. The Animal Research Ethics Committee of the
AutonomousUniversityofBarcelona (UAB)approved thestudy.
Experimental Design
Rats were sedated with sevoﬂurane and randomized to four
experimentalgroups (16animals/group).►Fig. 1 illustrates the
experimental design. ALI was induced by intratracheal instilla-
tion of LPS (Escherichia coli 055: B5, 10 µg/g body weight)
(SigmaChemical, St. Louis,MO).29Heparin (Vister, Parke-Davis,
Linate, Milan, Italy) was nebulized through Aeroneb system
(Philips Healthcare) at constant oxygen ﬂow (2 L/min). Rats in
the LPS/Hep group received twodoses of 1,000 IU/kg nebulized
heparin, administered 4 and 8 hours after LPS instillation. Rats
in the Hep/LPS/Hep group received three doses of nebulized
heparin: one dose 30 minutes before LPS instillation and one
dose 4 and 8 hours after LPS instillation. Rats in the LPS/saline
group received nebulized saline solution (0.9% NaCl) 4 and
8 hours after LPS instillation. Rats in the control group received
only saline solution, by tracheal instillation at the time of ALI
induction in the other animals and by nebulizer 4 and 8 hours
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afterwards. Animals were anesthetized (90 mg/kg ketamine
and 10 mg/kg xylazine) and exsanguinated 24 hours after LPS
instillation. BALF, lung tissue and blood were collected for
further analyses; BALF and lung homogenate were obtained
fromeight animals in each group, and the lungs for histological
examinationand lungwet/dryweight ratiowereobtained from
the remaining eight animals in each group.
Obtaining and Processing Bronchoalveolar Lavage
Fluid
The leftmain bronchuswas tiedwith a string at thehilum.BALF
from all animal groups was obtained from the right lung by
connecting a syringe to the cannula placed in the trachea and
then gently ﬂushing through it 5 mL sterile 0.9% NaCl solution
with 1-mM Ethylenediaminetetraacetic acid (EDTA) ﬁve times.
BALF volume recovery was always greater than 85%. BALF was
spun at 800  g for 10minutes and the supernatant was stored
at –80°C for subsequent analysis. Cells were counted using a
haemocytometer (Neubauer, Marienfeld, Lauda-Königshofen,
Germany), and slides were prepared by cytocentrifugation
(Shandon Cytospin 4, Thermo Electron Corporation, Marietta,
OH)andDiff-Quick staining (PanreacQuimicaSAU;Castellardel
Vallès, Spain). For each rat, approximately 500 cells were
counted.
Lung Wet/Dry Weight Ratio
Toassess oedema, the left lungwasdissected immediatelyafter
exsanguinationand thewetweightwas recorded. The lungwas
thenplaced in an incubator at 80°C for 48hours, the dryweight
recorded and the lung wet-to-dry weight ratio was measured.
Histological Examination
The right lungs were removed and ﬁxed in 4% paraformalde-
hyde. Two independent experts blinded to treatment analysed
4-µm sections excised of lung stained with haematoxylin and
eosin (H&E). The entire surface of the lung was analysed for
inﬂammation and damage, and was scored as follows: normal
lung (0), haemorrhage (on a 0–1 scale), peribronchial inﬁltra-
tion (on a 0–1 scale), interstitial oedema (on a 0–2 scale),
pneumocyte hyperplasia (on a 0–3 scale) and intra-alveolar
inﬁltration (on a 0–3 scale).
Cytokine and Protein Measurements
Total protein concentration in BALF was quantiﬁed using
the Micro BCA Protein Assay Kit (Pierce, Rockford, IL). IL-6,
GRO-κC, TNF-α and IL-10 in lung homogenate were deter-
mined by multiplex assay following the manufacturer’s
protocol (Luminex, Merck Millipore, Darmstadt, Germany).
PAI-1 in lung homogenate was determined by uniplex assay
(Luminex, Merck Millipore, Darmstadt, Germany). Levels of
TF, ﬁbrin degradation products (FDPs), and thrombin-anti-
thrombin complexes (TATc) in lung homogenate were mea-
sured by enzyme-linked immunosorbent assay (USCN Life
Sciences, Hubei, China).
Activated Partial Thromboplastin Time
Blood (0.3 mL) was collected from the abdominal aorta in
tubes containing 11-mM sodium citrate 24 hours after LPS
instillation. Activated partial thromboplastin time (aPTT)
was measured according to standard protocols (Echevarne
Laboratories, Spain).
Isolation of Alveolar Macrophages
BALF pellet from all animal groups was seeded in Petri dishes
with RPMI 1640 Medium supplemented with 10% foetal
bovine serum (FBS), 100 IU/mL penicillin and 100 µg/mL
streptomycin (Gibco, Langley, OK), for 1 hour at 37°C. The
supernatant was discarded and puriﬁed attached alveolar
macrophageswere cryopreserved in 500 µL of TRIzol reagent
(Ambion, Thermo Fisher Scientiﬁc, Madrid, Spain).
Fig.1 Experimental design. (a) Treatment group and (b) pre-treatment group.
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Alveolar macrophages’ purity was assessed by Diff-Quick
staining and immunoﬂuorescence. To perform immunoﬂuor-
escence, cellswereﬁxed in4%paraformaldehydeand incubated
for 2 hours in a blocking solution (3% FBS and 1% bovine serum
albumin in phosphate buffered saline [PBS]). Cells were then
incubated overnight with a mouse anti-rat CD68 antibody
(1:100) (Acris Antibodies, Rockville, MD), washed with PBS1X
and incubated at 37°C for 1 hour with a goat anti-mouse
IgG-FITC antibody (1:500) (Santa Cruz Biotechnology, Dallas,
TX). Cells were ﬁnally washed with PBS 1X and incubated
5minuteswithHOECHST (1:1,000) (Invitrogen,Waltham,MA).
RNA Extraction and Real-Time PCR
Total RNAwas extracted from isolated alveolar macrophages
using chloroform, isopropanol and ethanol. The optical den-
sity at 260 nm and the ratio 260 nm/280 nmwere measured
to determine the RNA purity (spectrophotometer ND-1000,
Nanodrop, Thermo Fisher Scientiﬁc, Wilmington, DE). Total
RNA was reverse-transcribed into cDNA with a reverse
transcriptase core kit (Eurogentec, Seraing, Belgium), using
an Alpho-SC (Analytik Jena AG, Jena, Germany) thermocycler.
DNAwas ampliﬁed in a real-time polymerase chain reaction
(PCR) system (7500 Real-Time PCR System, Applied Biosys-
tems, Thermo Fisher Scientiﬁc, Madrid, Spain) using SYBR
green (Kapa Biosystems, Cultek, Mataró, Spain) and the
corresponding rat primers (►Table 1). Data were corrected
by ΔΔCt method and shown as target gene expression
relative to Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and fold over saline group.
Statistical Analysis
Before starting the experiments, a power analysis was per-
formed using the Gpower 3 program. The analysis indicated
that 44 animalswere needed to detect large effects (0.5) with
85% power using an analysis of variance (ANOVA) test be-
tween factors with α at 0.05. We used 20 extra animals to
perform further investigational assessments. One-way AN-
OVAwith Fisher’s protected least-squares differences (PLSD)
test as post hoc analysis was used for multigroup compar-
isons (StatView 5.0.1; Abacus Concept, Berkeley, CA). Results
are reported as mean  SEM. Statistical signiﬁcance was set
at p < 0.05.
Results
Cellular and Histological Response
Compared with control rats, animals in the LPS-instilled
groups had higher total neutrophil counts in BALF; nebulized
heparin limited the increase in neutrophils (►Fig. 2a). There
were nomajor differences in totalmacrophage counts among
groups (►Fig. 2b). Compared with the LPS/saline group, only
heparin pre-treatment led to a decrease in the total number
of cells in BALF (Sal/Sal: 16.8  7.7, LPS/Sal: 45.7  5.7, LPS/
Hep: 40.8  6.8, Hep/LPS/Hep: 31.1  3.3; p < 0.05 vs. LPS/
Sal group). The total concentrations of BALF proteins
(►Fig. 2d) and the wet-to-dry ratio (►Fig. 2c) were signiﬁ-
cantly greater in LPS-instilled animals than in control ani-
mals, suggesting increased permeability of the
alveolocapillary barrier. Nebulized heparin markedly re-
duced total BALF proteins and the wet-to-dry ratio. Histolo-
gical analysis of lung tissue detected evidence of lung injury
(haemorrhage, interstitial oedema, peribronchial and intra-
alveolar inﬁltration, and alveolar pneumocyte hyperplasia)
in LPS-instilled rats; lung injury was considerably reduced
only in the Hep/LPS/Hep rats (►Fig. 3).
Coagulation Effects
LPS instillation increased lung-tissue levels of TF, TATc, FDP
and PAI-1 compared with control animals (►Fig. 4a–d re-
spectively). Nebulized heparin reduced lung TF, but TATc and
FDP levels decreased only in the Hep/LPS/Hep group. PAI-1
levels were not altered after heparin nebulization (►Fig. 4d).
Heparin had no effects on systemic coagulation, as no
changes were observed in the aPTT (data not shown).
Table 1 Rat primers
Gene Forward primer Reverse primer
GAPDH 5′ CTGTGCTTTCCGCTGTTTTC 3′ 5′ TGTGCTGTGCTTATGGTCTCA 3′
TNF-α 5′ AACTCCCAGAAAAGCAAGCA 3′ 5′ CGAGCAGGAATGAGAAGAGG 3′
iNOS 5′ CTTGGAGCGAGTTGTGGATT 3′ 5′ GGTGGGAGGGGTAGTGATG 3′
IL-10 5′ CATCCGGGGTGACAATAA 3′ 5′ TGTCCAGCTGGTCCTTCT 3′
Arginase-1 5′ GGGAAGACACCAGAGGAGGT 3′ 5′ TGATGCCCCAGATGACTTTT 3′
TGF-β 5′ TGCTTCAGCTCCACAGAGAA 3′ 5′ TGGTTGTAGAGGGCAAGGAC 3′
Smad 2 5′ ACTCGTGGGGGAAGAAAAGT 3′ 5′ CATGCTGCACTGCTTTGAAT 3′
Smad 3 5′ GACCAGGCATTTTGAGGAAA 3′ 5′ AGACCACAGCACCCCATAAG 3′
IRAK1 5′ TACAAAGTGATGGACGCCCT 3′ 5′ GGTGCCAGGCTGTAATGATG 3′
P-Selectin 5′ AGGTTGGCAATGGTTCACTC 3′ 5′ ACCATTGGGAGCTACACCTG 3′
CCL-2 5′ GCTGCTACTCATTCACTGGC 3′ 5′ GGTGCTGAAGTCCTTAGGGT 3′
TF 5′ ACAATCTTGGAGTGGCAACC 3′ 5′ TGGGACAGATAGGACCCTTG 3′
PAI-1 5′ AGGGGCAGCAGATAGACAGA 3′ 5′ CACAGGGAGACCCAGGATAA 3′
Plasminogen 5′ AAACGAAAGGGACTCCAGGT 3′ 5′ TCTCGAAGCAAACCAGAGGT 3′
Note: Table of the primers used for the real-time polymerase chain reaction.
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Fig. 2 Bronchoalveolar lavage analysis and wet/dry weight ratio. Absolute (a) neutrophil (PMN) and (b) alveolar macrophage (AM) cell counts
in the bronchoalveolar lavage ﬂuid of rats 24 hours after the induction of the injury. (c) Wet/dry weight ratio and (d) protein concentration in the
bronchoalveolar lavage ﬂuid. Data are presented as mean  SEM. ANOVA followed by the post hoc Fisher’s PLSD test were used. p < 0.05;
p < 0.001; p < 0.0001.
Fig. 3 Lung tissue analysis. (a–d) Representative images of haematoxylin and eosin staining lung tissue sections and (e) histological score in
animals 24 hours after induction of the injury. Original magniﬁcation200. Data are presented as mean  SEM. ANOVA followed by the post hoc
Fisher’s PLSD test were used. p < 0.05; p < 0.001; p < 0.0001.
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Fig. 4 Coagulant effectors and cytokines. (a) Tissue factor (TF), (b) thrombin–anti-thrombin complexes (TATc), (c) ﬁbrin degradation products
(FDPs), (c) plasminogen activator inhibitor type-1 activity (PAI-1), (e) IL-6, (f) TNF-α, (g) GRO-κC and (h) IL-10 concentrations were measured in
lung homogenate of animals 24 hours after induction of the injury. Data are presented as mean  SEM. ANOVA followed by the post hoc Fisher’s
PLSD test were used. p < 0.05; p < 0.001; p < 0.0001.
Fig. 5 Activation of alveolar macrophages. Gene expression of proinﬂammatory (M1): (a) TNF-α, (b) iNOS and alternative (M2), (c) IL-10,
(d) arginase-1 mediators in alveolar macrophages isolated from BALF of animals 24 hours after induction of the injury. Data are presented as
mean  SEM. ANOVA followed by the post hoc Fisher’s PLSD test were used. p < 0.05; p < 0.001; p < 0.0001.
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Inﬂammatory Response
In lung homogenates, concentrations of the proinﬂamma-
tory cytokines IL-6, TNF-α and GRO-κC diminished in both
groups of animals nebulizedwith heparin comparedwith the
LPS group (►Fig. 4e–g respectively). Levels of IL-10 were
higher in all the rat groups comparedwith control (►Fig. 4h).
Macrophage pathway
Alveolar macrophages were isolated from BALF (98%
purity; Supplementary Material 1). ►Fig. 5 reports the gene
expressionofM1proinﬂammatorycytokines (TNF-α [►Fig. 5a]
and iNOS[►Fig. 5b]) andM2regulatoryandreparativemarkers
(IL-10 [►Fig. 5c] and arginase-1 [►Fig. 5d]) from alveolar
macrophages. Nebulized heparin–deactivated alveolar macro-
phages stimulated with LPS; TNF-α, iNOS and arginase-1
expression signiﬁcantly decreased in both LPS/Hep and Hep/
LPS/Hep rats, but IL-10 expression signiﬁcantly decreased only
in the Hep/LPS/Hep group.
►Fig. 6 reports the expression of genes involved in
proinﬂammatory and coagulation pathways analysed in
alveolar macrophages. LPS had no effect on TGF-β expression
(►Fig. 6a) but increased the expression of Smad 3 (►Fig. 6b)
and Smad 2 (►Fig. 6c). Nebulized heparin diminished the
increase in Smad 3 expression in both groups, but dimin-
ished the increase in Smad 2 expression only in the Hep/LPS/
Hep group. LPS increased the expression of IRAK1 (►Fig. 6d),
p-selectin (►Fig. 6e) and CCL-2 (►Fig. 6f) in alveolar macro-
phages; CCL-2 and p-selectin expression were lower in the
Hep/LPS/Hep group. LPS increased expression in alveolar
macrophages of TF (►Fig. 6g), PAI-1 (►Fig. 6h) and plasmi-
nogen (►Fig. 6i), but only pre-treatment with nebulized
heparin mitigated the increase in plasminogen expression.
Discussion
The pathogenesis of ARDS involves both proinﬂammatory and
procoagulantmediators, andthebreakdownof theepithelialand
endothelial barrier results inpulmonaryoedemaand inﬁltration
of neutrophils in the alveolar space. In this rat model of LPS-
induced ALI, administrating nebulized heparin diminished re-
cruitment of neutrophils into the lung and attenuated pulmon-
arycoagulopathyand inﬂammationwithoutproducingsystemic
bleeding. Part of this positive effect of heparinmight be ascribed
to the alveolarmacrophages, inwhich the expression ofmarkers
of TGF-β effectors, NF-κB and coagulation pathways was de-
creased after heparin nebulization.
Fig. 6 Inﬂammatory and coagulation pathways of alveolar macrophages. Gene expression of TGF-β pathway: (a) TGF-β, (b) Smad 2 and (c)
Smad 3, NF-κB pathway, (d) IRAK-1, (e) p-selectin and (f) CCL-2 and coagulation pathway, (g) TF, (h) PAI-1 and (i) plasminogen in alveolar
macrophages isolated from BALF of animals 24 hours after induction of the injury. Data are presented as mean  SEM. ANOVA followed by the
post hoc Fisher’s PLSD test were used. p < 0.05; p < 0.001; p < 0.0001.
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Administering anti-coagulants directly to the lungs allows
higher dosages and increases local efﬁcacy without producing
systemic bleeding.19 We tested the effects of two nebulized
heparin treatment regimens. Rats in the LPS/Hep group
received two doses after ALI induction, while rats in the Hep/
LPS/Hepgroup receivedanadditionaldosebefore LPS.Although
the prophylactic pre-treatment plus treatment (Hep/LPS/Hep)
model canhelpelucidatemechanisms, the treatment (LPS/Hep)
model better reﬂects the clinical situation.Heparin reduced the
number of neutrophils and their recruitment in both groups.
Furthermore, heparin diminished lung permeability, reducing
the concentration of BALF proteins and oedema in both groups.
However, only in the pre-treatment group, heparin decreased
the number of total BALF cells and lung injury.
In theﬁrst stages of ALI/ARDS, proinﬂammatorymediators
inhibit natural anti-coagulant factors and induceprocoagulant
activity.18 In our ALI model, heparin nebulization decreased
pulmonary coagulation and inﬂammation. Previous studies
showed that nebulized heparin could reduce pulmonary
coagulopathy in an animal model of endotoxemia20 or pneu-
monia,30 although heparin did not produce any changes on
inﬂammation. This result could be attributed to the different
timing and dosage of heparin. In Hofstra et al’s experimental
model,20 heparinwas given every 6 hours, while in our model
the time interval between each heparin nebulization was
4 hours (heparin biological lifetime is 1.5 hours), although
we administrated fewer doses (three to the pre-treatment
group and two to the treatment group).
Alveolar macrophages play important roles in both the
development and resolution of ALI/ARDS.5–7 In our ALI model,
the expression of both proinﬂammatory (M1) and anti-inﬂam-
matory (M2) markers in alveolar macrophages increased after
LPS administration, with a predominant activation of the proin-
ﬂammatoryM1phenotype. Heparin attenuated the response of
alveolar macrophages during ALI, reducing M1 (TNF-α, iNOS)
and M2 (IL-10, arginase-1) markers to basal levels.
It has been shown that heparin anti-inﬂammatory effect
could be produced by the inhibition of NF-κB nuclear translo-
cation into the lung,18,26 reducing the expression of TNF-α and
IL-6.25,28,31 This is consistent with our results. Nebulized
heparin decreased proinﬂammatory cytokines in lung tissue
and theexpressionofNF-κBeffectors in alveolarmacrophages.
Moreover, some studies described that heparin ameliorated
lung injury induced by LPS in rats via the inhibition of nitric
oxide synthase expression and the TGF-β/Smad pathway.25 In
our model, heparin was also able to reduce the expression of
TGF-β effectors in alveolar macrophages.
The expression of TF by inﬂammatory cells such as macro-
phages acts as one of the primary initiators of thrombosis.32
Also, the release of TNF-α and IL-1β results in an increased TF
expression. During ARDS, it is known that alveolar macro-
phages increase their PAI-1 activity, inhibiting ﬁbrin degrada-
tion and promoting clots formation.10 In our LPSmodel, higher
levels of TF, TATc, PAI-1 and plasminogenwere found,mimick-
ing clinical ARDS.10,33 Nebulized heparin decreased TF and
TATc in lung tissue. It is known that TF expression on the
monocytes surface induces their interactionwith platelets and
endothelial cells through the union of p-selectin.34 Nebulized
heparin signiﬁcantly reduced p-selectin in alveolar macro-
phages. Furthermore, heparinwas able to reduce plasminogen
in alveolarmacrophages, indicating that heparinmay increase
ﬁbrinolysis through these cells. Accordingly, we ascertained
that alveolar macrophages promote the deposition of throm-
bus and formation of clots, conﬁrming that they are one of the
mainactors in thelinkbetween inﬂammationandcoagulation.
This study has some limitations. First, LPS administration is
a common ALI model that mimics human ARDS only in part,
because thismodel cannot reﬂect theheterogeneous aetiology
and management of ARDS. Second, the dose of heparin was
chosen fromprevious studies based on the efﬁcacy of the nose
exposure system, the evaporative water loss during nebuliza-
tion and the biological lifetime, and we cannot knowwhether
lower doses would have similar effects. Third, our Hep/LPS/
Hep group received an additional dose of heparin compared
with the LPS/Hep group; since the early administration of
heparin before LPS instillation might have reduced the devel-
opment of the injury, it is not possible to know whether the
differences between these two groups were due to the timing
of administration or to the total dose administered;moreover,
24 hours may not have been long enough to detect some
important histological changes in the LPS/Hep group.
Our experimental model focused on the acute phase of
lung injury. A prolonged treatment of nebulized heparin and
its effect in a late phase of ARDS need additional studies to
determine its long-term effects.
What Is Known on This Topic
• Acute respiratorydistress syndrome(ARDS) is associated
with pulmonary activation of coagulation and inﬂam-
mation. Previous studies suggest that anti-coagulants
mayhelprestorethecoagulationcascadeand treatARDS.
• It has been shown that nebulized heparin was able to
improve pulmonary coagulopathy in animal models of
acute lung injury (ALI) and in ARDS patients without
producing systemic bleeding.
• In vitro ﬁndings recently indicated that heparin may
exert its effects through alveolar macrophages.
What This Paper Adds
• Our data conﬁrmed that heparin nebulized directly into
the lungs reduced pulmonary coagulopathy in a rat
model of LPS-induced ALI without producing systemic
bleeding. We also demonstrated that nebulized heparin
signiﬁcantly ameliorated lung injury, decreasing inﬂam-
mation, permeability and neutrophils inﬁltration.
• We ascertained that heparin may act on alveolar
macrophages limiting the inﬂammatory response
through the reduction of TGF-β effectors, NF-κB and
coagulation pathways.
• In our rat model of ALI, nebulized heparin was effective
in attenuating pulmonary coagulopathy and inﬂamma-
tion. Some of the effects of heparin seem to be related
with alveolar macrophages. Preclinical data need to be
transferred to clinical studies to conﬁrm the potential
beneﬁt of nebulized heparin in ARDS patients.
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Conclusion
In our rat model of ALI, nebulized heparin was effective in
attenuating pulmonary coagulopathy and inﬂammation.
Some of the effects of heparin seem to be related with
alveolar macrophages. Preclinical data need to be transferred
to clinical studies to conﬁrm the potential beneﬁt of neb-
ulized heparin in ARDS patients. A better understanding of
the mechanisms involved in the pathogenesis of ARDSmight
open new ﬁelds for the treatment of this disease.
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